EUVIMEDEUVIMED entdecken
VergleichsstudieMultizentrische StudieBeobachtungsstudie

MSI-H locally recurrent rectal cancer: Immune checkpoint inhibitors vs. standard chemotherapy and pelvic exenteration

Luca Sorrentino, Vincenzo Nasca, Elena Daveri, Sara Lonardi, Francesca Bergamo, Rossana Intini, Andrea Scardino, Isacco Montroni, Filippo Pietrantonio

Digestive and Liver Disease · 2025

DOI: 10.1016/j.dld.2025.08.001 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Digestive and Liver Disease, 2025. Verfasst von Luca Sorrentino und 8 weiteren Autor:innen. Beteiligte Einrichtung: Gynecological Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. Electronic address: luca.sorrentino@istitutotumori.mi.it. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Neoplasm Recurrence, Local, Pelvic Exenteration, Rectal Neoplasms. Die Arbeit nennt 24 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Locally recurrent rectal cancers (LRRC) require exenterative surgery and pelvic re-irradiation to achieve R0 margins, which are the strongest predictor of survival. Data on immune checkpoint inhibitors (ICIs) in deficient mismatch repair (dMMR)/microsatellite instability-high (MSI-H) LRRC are scarce. AIMS: To assess efficacy and short-term outcomes of pelvic exenteration and chemotherapy/(re)chemoradiation vs. ICIs in dMMR/MSI-H LRRC patients. METHODS: A multicenter study was conducted including patients affected by dMMR/MSI-H LRRC treated from 2009 to 2024 at 3 Italian centers. Short-term outcomes were assessed, including the rate of exenterative procedures, definitive ostomy rate, and quality of life issues. 3-yr progression-free survival (3y-PFS) was also analyzed. RESULTS: Eight patients were treated with ICI and 6 with standard treatment. Pelvic exenteration was performed in 66.7 % of cases in the standard treatment group vs. 12.5 % with ICI (p = 0.04). The definitive stoma rates were respectively 66.7 % and 12.5 % (p = 0.04). Quality of life was affected in 80.0 % of patients undergoing exenterative surgery, mainly related to urinary infections and/or fistula. 3-yr PFS was 51.4 % with ICI vs. 33.3 % with standard treatment (HR 0.35, p = 0.13). CONCLUSION: The use of ICIs might be an effective treatment for dMMR/MSI-H LRRC, avoiding pelvic exenteration and its consequences in the majority of patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immune Checkpoint InhibitorsNeoplasm Recurrence, LocalPelvic ExenterationRectal NeoplasmsAdultAgedFemaleHumansMaleMiddle AgedChemoradiotherapyDNA Mismatch RepairItalyMicrosatellite InstabilityQuality of LifeRetrospective Studies

Stichwörter der Autor:innen

Immune checkpoint inhibitorsLocally recurrent rectal cancerMicrosatellite instabilityPelvic exenteration

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Gynecological Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. Electronic address: luca.sorrentino@istitutotumori.mi.it.
  • Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
  • Unit of Translational Immunology, Department of Experimental Oncology, Fondazione IRCCS, Istituto Nazionale dei Tumori di Milano, Milan, Italy.
  • Medical Oncology 1, Istituto Oncologico Veneto Istituto di Ricovero e Cura a Carattere Scientifico, Padua, Italy.
  • Colorectal Surgery Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy. Electronic address: filippo.pietrantonio@istitutotumori.mi.it.

Zitieren

APA

Sorrentino, L., Nasca, V., Daveri, E., Lonardi, S., Bergamo, F., Intini, R., Scardino, A., Montroni, I., & Pietrantonio, F. (2025). MSI-H locally recurrent rectal cancer: Immune checkpoint inhibitors vs. standard chemotherapy and pelvic exenteration. Digestive and Liver Disease. https://doi.org/10.1016/j.dld.2025.08.001

Vancouver

Sorrentino L, Nasca V, Daveri E, Lonardi S, Bergamo F, Intini R, et al. MSI-H locally recurrent rectal cancer: Immune checkpoint inhibitors vs. standard chemotherapy and pelvic exenteration. Digestive and Liver Disease. 2025. doi:10.1016/j.dld.2025.08.001

BibTeX
@article{Sorrentino2025,
  author = {Sorrentino, Luca and Nasca, Vincenzo and Daveri, Elena and Lonardi, Sara and Bergamo, Francesca and Intini, Rossana and Scardino, Andrea and Montroni, Isacco and Pietrantonio, Filippo},
  title = {MSI-H locally recurrent rectal cancer: Immune checkpoint inhibitors vs. standard chemotherapy and pelvic exenteration},
  journal = {Digestive and Liver Disease},
  year = {2025},
  doi = {10.1016/j.dld.2025.08.001}
}
Kostenlos starten →